StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP operating income (loss) by Year

Non-GAAP operating income (loss) ($M) ($M)

QuarterlyAnnual

Gilead Sciences Non-GAAP operating income (loss): $13,193M in FY2025, up 54.8% from a year earlier.

Latest, FY2025
13,193
Period ended Dec 31, 2025
Change on a year earlier
+54.8%
8,520 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below

Where the FY2025 figure comes from

“|| Non-GAAP operating income | $ | 3,089 | $ | 3,114 | $ | 13,193 | $ | 8,520”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP operating income (loss) ($M) ($M)Year on yearSource
FY2025Dec 31, 202513,193+54.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
FY2024Dec 31, 20248,520-18.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
FY2023Dec 31, 202310,484-13.9%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
FY2022Dec 31, 202212,180-1.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
FY2021Dec 31, 202112,390+5.9%Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
FY2020Dec 31, 202011,704–Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP operating income (loss) ($M), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-op-inc

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.